Is This Really the Best Pipeline In Biotech?
Any disappointment from ISIS Pharmaceuticals recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month.
Wall Street is incredibly excited as well, with Piper Jaffray boldly declaring Isis as having the best pipeline in biotech and an obvious takeover target.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass talk Isis' large drug pipeline, its clincal trial success, and why ISIS could be attracting buyout attention.
Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article Is This Really the Best Pipeline In Biotech? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Isis Pharmaceuticals. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.